Invest in

Drug-Patent Cliffs

13.4%
0.1%
0.5%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
13.4%
0.1%
0.5%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 15.8%
18.6% Dr. Reddy's Laboratories Ltd RDY 20.1%
18.2% Taro Pharmaceutical Industries Ltd. TARO 22.8%
18.2% Mylan N.V. MYL 6.2%
8.8% Impax Laboratories Inc. IPXL 37.8%
8.4% Abbott Laboratories ABT 2.5%
8.0% The Medicines Company MDCO 1.5%
7.4% Mallinckrodt plc MNK 3.8%
7.3% Akorn Inc. AKRX 24.1%
2.8% Lannett Co Inc LCI 43.2%
1.2% Cambrex Corporation CBM 4.6%
1.2% Endo International PLC ENDP 73.1%

Quotes delayed 15 mins. Currently Sep 25, 2016 1:23:40 AM. Fields are marked with -- when data is unavailable.